[ad_1]
Annexon, Inc. (NASDAQ:ANNX) is likely one of the 12 scorching penny shares to put money into proper now.
On November 19, 2025, The Fly reported that Wells Fargo elevated its worth goal on Annexon, Inc. (NASDAQ:ANNX) from $14 to $27, whereas reiterating an “Chubby” ranking. The funding agency’s worth revision displays its elevated chance of success within the second half of 2026 for vonaprument’s Part 3 trial in GA to 55% from 10%. The agency believes this system presents a big, uneven risk-reward skew with large upside within the subsequent 12 months.
In the meantime, Annexon, Inc. (NASDAQ:ANNX) reported Q3 2025 outcomes on November 10. Posting $54.9 million, or $0.37 per share, in web loss for the quarter, the corporate’s R&D bills elevated to $49.7 million attributable to development of vonaprument’s Part 3 ARCHER II trial and world filings for tanruprubart in GBS. Alternatively, G&A bills decreased, due to the corporate’s operational efficiencies.
Annexon, Inc. (NASDAQ:ANNX) closed the quarter with $188.7 million in money, offering a runway into early 2027. The corporate’s neuroinflammation platform additionally famous progress, with EU Advertising and marketing Authorization Utility (MAA) submission for tanruprubart in January 2026 and topline ARCHER II information for vonaprument anticipated within the second half of 2026.
Annexon, Inc. (NASDAQ:ANNX) is targeted on growing progressive complement inhibitors concentrating on neuroinflammation throughout autoimmunity, neurodegeneration, and ophthalmology.
Whereas we acknowledge the potential of ANNX as an funding, we imagine sure AI shares provide larger upside potential and carry much less draw back danger. In the event you’re on the lookout for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: 10 Greatest Small-Cap Biotech Shares to Purchase In keeping with Analysts and 11 Missed Tech Shares to Make investments In.
Disclosure: None.
[ad_2]
